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Abstract 
Clostridium difficile has been historically viewed as a hospital acquired infection. However, the 
emergence of community acquired infection in low risk populations, the identification of new 
risk factors, detection of a hypervirulent strain of C. difficile, and increasing mortality have 
changed the epidemiology if this infection. Current standards of treatment have come into 
question due to increasing recurrence rates and treatment failures, possible resistance of 
Metronidazole, and concerns surrounding Vancomycin resistant enterococci (VRE). Fidaxomicin, 
a narrow-spectrum macrolide, is the first drug approved by the FDA in 20 years for the 
treatment of C. difficile infection. It has shown good in vitro and in vivo activity, has similar 
clinical cure rates, lower recurrence rates, and higher global cure rates compared to 
Vancomycin in non-hypervirulent strains and similar efficacy in all outcomes in the 
hypervirulent strain. Overall, Fidaxomicin appears to be a reasonable second line treatment 
option for recurrent C. difficile infection in patients who have failed to respond to treatment 
under the current guidelines. 
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Introduction 
Clostridium difficile (C. difficile), an opportunistic gram positive, anaerobic, spore-
forming bacillus, is the most widely recognized cause of infectious diarrhea with a high 
healthcare cost burden (McFarland, 2008). There are two primary virulence factors found in C. 
difficile infections, toxin A and toxin B (Warny, et al., 2005). These toxins bind to surface 
proteins in the intestinal epithelial cells and disrupt the cytoskeleton resulting in a rounding of 
the cell, opening of the tight junction between cells and a subsequent fluid release resulting in 
diarrhea (McFarland, 2008; Noren, 2010). Toxin A is unique in that it also induces apoptosis of 
the cells (McFarland, 2008). Depending on the virulence of the toxin and the host response, C. 
difficile can cause a wide array of symptoms ranging from mild, watery diarrhea to life 
threatening conditions including: fulminant pseudomembranous colitis, toxic mega colon, 
bowel perforation, septic shock and death (LoVecchio & Zacur, 2011; McFarland, 2008). Higher 
incidence rates, changing epidemiology, the emerging hypervirulent strain and apparent 
decreased efficacy of current treatment options have piqued much interest into the cause and 
transmission of C. difficile as well as renewed interest in the pursuit of new treatments for this 
disease. 
Incidence of C. difficile 
The rates of C. difficile have been climbing in the last 15 years with a dramatic rise in 
mortality. The CDC reports an eight-fold increase in the number of deaths due to C. difficile 
from 1999 to 2006 (Xu, Kochanek, Murphy & Tejada-Vera, 2010). In 2006, C. difficile was added 
to the rankable causes of death and is listed as one of the 20 leading causes of death for the 
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elderly accounting for nearly 92% of all deaths from C. difficile (Xu, Kochanek, Murphy & 
Tejada-Vera, 2010). This is in part due to the changing epidemiology of C. difficile infection. 
Historically, the populations at greatest risk for contracting C. difficile have been those 
with traditional risk factors which include: previous antibiotic exposure, advanced age, co-
morbid conditions, feeding tubes, immune suppression/compromise, previous episode of C. 
difficile infection, mucosal damage from chemotherapy or radiation, and hospitalizations 
(LoVecchio & Zacur, 2011; Freeman, et al., 2010; Noren, 2010). However, there have been 
increasing reports of C. difficile in atypical populations. Multiple reports have described a 
growing number of C. difficile infections emerging in the community in persons without the 
classic risk factors, including recent exposure to antibiotics, which have been implicated in the 
acquisition of this infection in children, peripartum women and young adults (Khanna, Pardi, 
Aronson, Kammer & Baddour, 2012; Kuntz, Chrischilles, Pendergast, Herwaldt & Polgreen, 
2011; McFarland, 2008). It has been postulated that shorter inpatient lengths of stay have led 
to community identification of nosocomial infections (Prabaker & Weinstein, 2011). 
Hypervirulent Strain 
Complicating the epidemiology of this disease is the emergence of a hypervirulent strain 
of C. difficile, B1/NAP1/027 (McFarland, 2008). This hypervirulent strain has been implicated in 
multiple epidemic outbreaks in Canada and the United States since 1999. The B1/NAP1/027 
strain can produce 16 times more toxin A and 23 time more toxin B than non-epidemic strains, 
is resistant to fluoroquinolones, and has higher morbidity and mortality rates than non-
epidemic strains (LoVecchio & Zacur, 2012; McFarland, 2008; Warny, et al., 2005). To date, this 
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hypervirulent strain of C. difficile has been identified in 40 states in the U.S. as well as epidemic 
outbreaks in countries globally (Freeman, et al., 2010; Gerding, 2010).   
Risk Factors 
Exposure to high risk antibiotics remains the primary risk factor for C. difficile 
acquisition. Historically, the antibiotic most strongly implicated in the induction of C. difficile 
infection was clindamycin (Freeman, et al., 2010). However, more recently many other 
antibiotics have come into favor as the cause for C. difficile as the use or misuse of these 
medications continues to rise. All antibiotics have the potential to interrupt the normal flora of 
the bowel thereby altering the effectiveness of competitive exclusion and increasing the 
susceptibility of patients to C. difficile contraction (LoVecchio & Zacur, 2012; McFarland, 2008). 
Preservation of the normal flora, mainly comprised of the Clostridium and Bacteroides groups 
as well as Lactobacillus, and Bifidobacterium is important to maintain competitive exclusion 
(Noren, 2010). The fluoroquinolones specifically have been attributed to the increasing rates of 
C. difficile (Freeman, et al., 2010; McFarland, 2008; Noren, 2010).  
In addition to antibiotic exposure, several other risk factors have been identified 
including age (>65), compromised immune system and comorbid conditions (Freeman, et al., 
2010; LoVecchio & Zacur, 2012; McFarland, 2008). The number of hospitalizations and lengths 
of stay have also been identified as contributing risk factors (Freeman, et al, 2010; McFarland, 
2008). More recently new sources of susceptibility for C. difficile have been described including 
animals and food, the use of feeding tubes, and the use of proton pump inhibitors, the latter of 
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which remains highly controversial (Freeman, et al, 2010; Gerding, 2010; LoVecchio & Zacur, 
2012; McFarland, 2008; Noren, 2010). 
Current Standards of Treatment 
LoVecchio & Zacur (2011) describe the properties that pharmacologic therapy for C. 
difficile should possess including: oral administration ability, high activity levels in the colon, low 
systemic absorption and preservation of normal flora in the colon. Current guidelines call for 
discontinuing the offending agent and instituting antimicrobial therapy with oral Metronidazole 
or Vancomycin (Cohen, et al., 2010). These are the only two drugs recommended for therapy 
but Metronidazole has high systemic absorption with low fecal concentration whereas 
Vancomycin has poor systemic absorption and high levels of fecal concentration (Cohen, et al., 
2010).  
According to the Infectious Diseases Society of America (IDSA) guidelines, 
Metronidazole is the first line treatment for mild-moderate disease but is not approved by the 
Food and Drug Administration (FDA) for use in C. difficile and its efficacy appears to be declining 
(Cohen, et al., 2010; McFarland, 2008; Miller, 2010). Interestingly, Metronidazole has also been 
given a specific black box warning stating “Unnecessary use of the dug should be avoided. Its 
use should be reserved only for conditions for which it is approved” (FDA, 2010). For first 
recurrence of infection, repeating treatment with the initial choice of drug is recommended. 
However, if Metronidazole fails, is poorly tolerated, or contraindicated, second line treatment is 
Vancomycin (Cohen, et al., 2010). Repeated recurrences call for use of Vancomycin only in 
tapered or pulse dosing as Metronidazole has the “potential for cumulative neurotoxicity” 
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(Cohen, et al., 2010, p. 433). However, even with Vancomycin high rates of failure and 
recurrence have been described which may be, in part, due to colonization with VRE and the 
emergence of B1/NAP1/027 (Choi, et al., 2011; LoVecchio & Zacur, 2012; Prabaker & Weinstein, 
2011; Tannock, et al., 2010).  
Metronidazole is more cost-effective but has a higher systemic absorption than 
Vancomycin which may be the reason for treatment failures with this therapy. Others have 
suggested that C. difficile has become resistant to therapy with Metronidazole (Freeman, et al., 
2010; McFarland, 2008; Miller, 2010). However, recurrence rates ranging from 5-47% have 
been described with current treatment options (Choi, et al., 2011; LoVecchio & Zacur, 2012; 
McFarland, 2008).  Current standards of treatment have come into question due to the high 
rates of treatment failure and recurrence.  
The rates of recurrence and treatment failures, increasing morbidity and mortality, 
systemic absorption, few treatment options and emergence of the hyper virulent strain have 
raised concern regarding the current treatment options. Optimer Pharmaceuticals has recently 
received FDA approval for Fidaxomicin, a narrow spectrum macrocyclic antibiotic, for the 
treatment of mild to moderate C. difficile infections and is the first drug to be approved for use 
in C. difficile in 25 years (Peterson, 2011). The aim of this study is to review the available 
evidence to determine whether fidaxomicin for the treatment of mild to moderate clostridium 
difficile infection improves cure rates and decreases the episodes of recurrence as compared to 
vancomycin.  
Fidaxomicin Versus Current Standard of Treatment 
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Pharmacokinetics 
 Minimum inhibitory concentrations (MIC) are crucial in determining the efficacy of a 
medication. A low MIC indicates the lowest concentration of a drug that will inhibit the growth 
of the bacteria in question. In the case of C. difficile infection, the MIC against both C. difficile 
and the normal bacterial flora become important to understand as preservation of the normal 
flora is an important component of efficacious treatment.  
In 2004, two quasi-experimental studies were published assessing the in vitro activity of 
Fidaxomicin (formerly known as OPT-80) against several hundred anaerobic intestinal bacteria. 
MICs were measured in both of these studies and compared to multiple other antibacterial 
agents including Vancomycin and Metronidazole. Table 1 summarizes the findings of 
Fidaxomicin, Vancomycin, and Metronidazole against C. difficile, all clostridium species, 
bacteroides fragilis, lactobacillus and bifidobacteria. Both studies showed good activity for 
Fidaxomicin, Vancomycin, and Metronidazole against Clostridium species but with varying MIC 
ranges between studies (Credito & Appelbaum, 2004; Finegold, et al., 2004). Superior activity of 
Fidaxomicin against C. difficile was shown in both studies. Credito & Appelbaum (2004) found 
that Fidaxomicin had superior activity against C. difficile and all clostridium species versus 
Vancomycin and Metronidazole, was equivalently active against lactobacillus, bifidobacteria, 
and had less activity against bacteroides fragilis than the two current recommended 
medications. This would presumably result in higher preservation of normal gut flora in vivo.  
In contrast, Finegold, et al. (2004) found that Fidaxomicin was only superior to 
Vancomycin in certain clostridium species, specifically clostridial clusters I and XI (including C. 
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difficile), had more activity against lactobacillus and bifidobacteria than Metronidazole but not 
Vancomycin, and markedly less activity against the bacteroides group and clostridial clusters 
XIVa, XI, and XIII than either Vancomycin or Metronidazole. Of note is the variation in the MICs 
reported between studies. Finegold, et al. (2004) used a Wadsworth agar dilution technique 
whereas Credito & Appelbaum (2004) used a Brucella agar with sheep blood. This difference in 
technique may account for the variation in MIC results. However, the results of both studies 
support the narrow-spectrum activity of Fidaxomicin which is a desirable trait for antimicrobial 
therapy for C. difficile. 
The in vivo efficacy of Fidaxomicin was evaluated in two small open-label Phase 2A 
randomized dose-finding trials in which authors tested fecal samples of patients for spared 
normal bacterial flora after treatment with Fidaxomicin versus Vancomycin. The return of 
normal flora, specifically clostridial clusters XIVa and IV, increased during and after treatment 
with Fidaxomicin but was not statistically significant (p>0.05), whereas Vancomycin reduced the 
population of these clusters as well as bifidobacteria with statistical significance (p<0.05) 
(Tannock et al., 2010). This study also reported a statistically significant increase in lactobacilli 
and enterococci in the Vancomycin treatment group (p<0.05) which was “coincident with the 
decrease in proportions of clostridial clusters and bifidobacteria” (Tannock, et al., 2010, p. 
3357).  In another study, Fidaxomicin was reported to suppress C. difficile (no p-value given) 
and lower recurrence (p=0.03) when compared to Vancomycin with no alteration in bacteroides 
(p=0.11-0.56) (Louie, et al., 2009). While the latter outcome was not statistically significant, in 
the Vancomycin treatment group alteration in bacteroides was significant (p=0.03) (Louie, et al., 
2009).  
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In an additional Phase 2, dose-finding, randomized, open-label study by Louie, et al. 
(2009), plasma and fecal levels of Fidaxomicin were measured to assess systemic absorption 
and colonic retention of the drug. Plasma levels were found to be less than 20ng/ml in all 
subjects receiving the 200mg twice daily dosing and a high fecal concentration of 1433 ± 975 
μg/ml (Louie, et al., 2009). These results were supported in their Phase 3 clinical trial which 
showed mean plasma concentrations of 22.8 ± 26.5 ng/ml and mean fecal concentrations of 
1225 ± 759.0 μg/g (Louie, et al., 2011). These studies did not compare Fidaxomicin levels 
against Vancomycin levels. While no statistical significance was reported, this is clinically 
significant as effective treatment for C. difficile must have low systemic absorption and high 
fecal concentrations to be effective.   
Clinical cure and recurrence 
Clinical efficacy of Fidaxomicin versus Vancomycin was reported in three studies, two 
large randomized control trials and a systematic review. Initial clinical cure, recurrence and 
global cure were reported in both trials. Global cure was not reported in the systematic review. 
The studies are summarized in Table 2 with demographics and interventions outlined in Table 3. 
 Clinical cure. 
  Clinical cure was defined by the authors as resolution of diarrhea which is maintained 
until 2 days after treatment completion (Louie, et al., 2011; Mullane, et al., 2011). Fidaxomicin 
clinical cure rates were found to be non-inferior to Vancomycin in all three studies. Drekonja, et 
al. (2011) reported no significant difference between Fidaxomicin and Vancomycin, giving no p-
value. When given with a concomitant antibiotic, Fidaxomicin was found to have higher clinical 
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cure than Vancomycin (p=0.04) but the clinical cure rate in the presence of high-risk 
concomitant antibiotics did not reveal a statistical significance (p=0.09) (Mullane, et al., 2011). 
One study reported clinical cure rates in Fidaxomicin for the modified intention to treat (mITT) 
and per protocol (PP) groups as non-inferior to Vancomycin “with a lower boundary of the 
97.5% CI for the difference in cure rates of -3.1…[and] -2.6 percentage points” respectively 
(Louie et al., 2011).  
  Recurrence. 
 Recurrence rates were reported by all three studies. Clinical recurrence was defined in 
the randomized control trials as the reappearance of symptoms (more than three unformed 
stools per day) within 4 weeks after completion of therapy, C. difficile toxin A or B, or both in 
stool, and treatment requirement for infection (Louie, et al., 2011; Mullane, et al., 2011). Louie, 
et al. (2011) reports statistically significant lower recurrence rates with Fidaxomicin in both the 
mITT group (p=0.005) and the PP group (p=0.004). This study did show similar rates of 
recurrence between Fidaxomicin and Vancomycin on the B1/NAP1/027 hyper virulent strain 
which was not statistically significant (p=0.93) (Louie, et al., 2011). Administration of 
Fidaxomicin with concomitant antibiotics, was found to have increased recurrence rates but it 
did not reach statistical significance (p=0.48) and in conjunction with high risk antibiotics the 
difference in rate of recurrence between Fidaxomicin and Vancomycin was not statistically 
significant (p=0.54) (Mullane, et al., 2011). In a systematic review, Drekonja, et al. (2011) found 
that the overall recurrence rate for Fidaxomicin was lower than Vancomycin (p=0.005). 
  Global Cure. 
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 Global cure is defined as “clinical cure with no recurrence” (Mullane, et al, 2011). Two 
studies reported results for global cure. Louie, et al. (2011) reports a statistically significant 
global cure rate for Fidaxomicin in both the mITT and PP groups with p=0.006 for both groups. 
In a study evaluating cure rates with concomitant antibiotic use, global cure rate was 
statistically significant (p=0.02) except when adjunctive high risk antibiotics were used (p=0.18) 
(Mullane, et al., 2011). 
Strengths/Limitations 
The studies conducted by Louie, et al. (2011) and Mullane, et al. (2011) were both 
double-blind randomized control trials. This approach has strong rigor, lends itself to 
generalizability and has strong external validity due to the “natural” setting. The remaining 
studies were quasi-experimental with quite small samples sizes which weakens the 
generalizability and external validity of these studies. Additionally, no study reported power 
analysis or effect size which further weakens their external validity. The results of these studies 
must be interpreted with caution. Bias is a major concern with each of the studies evaluated as 
it was either funded by Optimer pharmaceuticals, the manufacturer of Fidaxomicin, or written 
by an investigator employed by said manufacturer. The systematic review provides the 
strongest form of evidence and lessens the bias that may be present in the other studies.   
Discussion 
Fidaxomicin is the first antibiotic to be approved by the FDA for treatment of C. difficile 
in 20 years. It has good in vitro and in vivo efficacy, has been shown to be non-inferior to Vanco 
in clinical trials, in both epidemic and non-epidemic strains, and appears to significantly 
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decrease the rate of recurrent infection. Additionally, it meets the criteria for effective 
treatment of C. difficile: It is given orally, has low systemic absorption, high fecal concentrations 
and preserves the normal bacterial flora of the bowel, which the current treatments do not. 
Fidaxomicin appears to be a reasonable alternative therapy for recurrent C. difficile but 
not for initial treatment. As the only randomized control studies that have been published were 
conducted by Optimer Pharmaceuticals, bias is a concern. Large, independent trials are 
warranted to provide a clearer picture of its overall efficacy against C. difficile and superiority in 
treatment versus Vancomycin.  
Additionally, pharmacoeconomics cannot be disregarded when choosing therapy. In a 
review of this new drug, Grant (2011) reports wholesale pricing of Fidaxomicin much higher 
than Vancomycin for a 10-day course of treatment ($2,800 versus $1,061 respectively). Retail 
pricing shows Fidaxomicin is $3,260.19 for a 10-day course as opposed to Vanco which is $1,365 
and Metronidazole is markedly less expensive than either of these drugs at $27 for a 10-day 
course (N. Bidinger, personal communication, April 2, 2011). It may be reasonable to offset the 
concern of cost with decreased recurrence rates in those patients who experience recurrent 
infection. However, this will prohibit many providers from prescribing and will not be covered 
under health insurance plans requiring, at minimum, a pre-authorization for coverage.  
For health care providers, prudent prescription of antimicrobial agents is of utmost 
importance in preventing the contraction of C. difficile. If a high-risk antimicrobial must be used, 
such as Clindamycin or a flouroquinolone, signs and symptoms of C. difficile should be included 
in the counseling of patient, such as more than three watery stools a day, abdominal cramping, 
FIDAXOMICIN IS A SUPERIOR TREATMENT TO VANCOMYCIN FOR RECCURENT CLOSTRIDIUM 
DIFFICLE INFECTION   14 
fever, nausea, and dehydration so the offending agent can be discontinued and treatment for 
the infection can be instituted early (Mayo Clinic, 2010).   
Polymerase chain reaction (PCR) testing is generally used to assess the presence of C. 
difficile in stool. This test is rapid, with high sensitivity and specificity (Cohen, et al., 2010). 
However, current guidelines report that more data is still needed on PCR testing before an 
official recommendation will be issued for use of PCR (Cohen, et al., 2010). Rather, guidelines 
state that identification of the infection should be obtained using an enzyme immunoassay test 
(EIA) to screen followed by a toxinogenic culture for confirmation (Cohen, et al., 2010). The 
IDSA guidelines support this method as an “interim recommendation” pending more data on 
sensitivity and support stool culture as the gold standard but acknowledge that “stool culture is 
not clinically practical because of its slow turnaround time” (Cohen,  et al., 2010, p.9).  
If recurrent C. difficile is diagnosed with failed response to current treatment guidelines, 
Fidaxomicin is a reasonable next line therapy. Patients should be counseled on duration of 
treatment (10 days of twice daily dosing), side effects of the medication including abdominal 
pain, nausea and vomiting, anemia, and neutropenia, as well as the more serious side effects of 
bowel obstruction and gastrointestinal hemorrhage (FDA, 2011). Follow-up should occur after 
therapy and with any progression of disease symptoms, non-resolution of symptoms, and 
recurrence of infection.   
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Table 1. In vitro activity of Fidaxomicin, Vancomycin and Metronidazole against select bacterial isolates 
Study   Bacterial group   Antimicrobial agent  MIC50  MIC90  
Finegold, et al (2004) C. difficile  Fidaxomicin   0.12  0.25 
      Vancomycin   1  2 
      Metronidazole   0.25  0.5 
   All clostridium species Fidaxomicin   0.062  128 
      Vancomycin   1  16 
      Metronidazole   ≤0.5  1.0 
Miscellaneous gram-positive Fidaxomicin   1  32.0 
  non-spore-forming rods  Vancomycin   1  2 
  Includes lactobacillus and Metronidazole   4.0  >128 
bifidobacteria 
   Bacteroides fragilis Fidaxomicin   256  1024 
      Vancomycin   64  128 
      Metronidazole   1  4 
Credito, et al (2004) C. difficile  Fidaxomicin   ≤0.016  0.25 
      Vancomycin   0.5  2.0 
      Metronidazole   ≤0.125  0.5 
   All clostridium species Fidaxomicin   ≤0.016  0.25 
      Vancomycin   0.25  2.0 
      Metronidazole   ≤0.125  2.0 
  Miscellaneous gram-positive Fidaxomicin   0.25  16.0 
  non-spore-forming rods  Vancomycin   0.25  16.0 
  Includes lactobacillus and Metronidazole   2.0  >16.0 
bifidobacteria 
   Bacteroides fragilis Fidaxomicin   64.0  >128 
      Vancomycin   >16.0  >16.0 
      Metronidazole   0.25  1.0 
MIC50  - MIC at which 50% of isolates tested were inhibited 
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Table 2. Efficacy of Fidaxomicin versus Vancomycin in clinical cure rates, recurrence, and global cure 
rates 
Author    Clinical cure   Recurrence  Global cure  
Drekonja, et al (2011)  no significant difference p=0.005  not reported 
Louie, et al (2009) 
         mITT group  -3.1 percentage points  p=0.005  p=0.006 
         PP group   -2.6 percentage points  p=0.004  p=0.006 
 
Mullane, et al (2011)  
         With any CA antibiotic P=0.04    p=0.048  p=0.02 
         With high-risk antibiotic p=0.09    p=0.54   p=0.18  
mITT: modified intention to treat group 
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Table 3. Demographics and interventions of studies examining the efficacy of Fidaxomicin versus 
Vancomycin in clinical cure rates, recurrence, and global cure rates 
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mITT: modified intention to treat; PP: pre protocol; IV: independent variable; DV: dependent variable 
RCT: Randomized control trial 
 
 
FIDAXOMICIN IS A SUPERIOR TREATMENT TO VANCOMYCIN FOR RECCURENT CLOSTRIDIUM 
DIFFICLE INFECTION   18 
References 
Choi, H.K., Kim, H., Lee, S.H. & Lee, S.J. (2011). Risk factors for recurrence of Clostridium difficile 
 infection: Effect of Vancomycin-resistant Enterococci colonization. Journal of Korean 
 Medical Science, 26, 859-864. doi: 10.3346/jkms.2011.26.7.859 
Cohen, S.H., Gerding, D.N., Johnston, S., Kelly, C.P., Loo, V.G., McDonald, L.C.,…Wilcox, M.H. 
 (2010). Clinical practice guidelines for Clostridium difficile infection in adults: 2010 
 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious 
 Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology, 31, 
 431-455.  
Credito, K.L. & Appelbaum, P.C. (2004). Activity of OPT-80, a novel macrocycle, compared to 
 those of eight other agents against selected anaerobic species. Antimicrobial Agents 
 and Chemotherapy, 48, 4430-4434. Doi: 10.1128/AAC.48.11.4430-4434.2004 
Drekonja, D.M., Butler, M., MacDonald, R., Bliss, D., Filice, G.A., Rector, T.S.,…Wilt, T.J. (2011). 
 Comparative effectiveness of Clostridium difficile treatments, A systematic review. 
 Annals of Internal Medicine, 155, 839-848.  
Finegold, S.M., Molitoris, D., Vaisanen, M.L., Song, L., Liu, C. & Bolaños, M. (2004). In vitro 
 activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrobial 
 Agents and Chemotherapy, 48, 4898-4902. doi: 10.1128/AAC.48.12.4898-4902.2004  
FIDAXOMICIN IS A SUPERIOR TREATMENT TO VANCOMYCIN FOR RECCURENT CLOSTRIDIUM 
DIFFICLE INFECTION   19 
Freeman, J., Bauer, M.P., Baines, S.D., Corver, J., Fawley, W.N.,…Wilcox, M.H. (2010). The 
 changing epidemiology of Clostridium difficile infections. Clinical Microbiology Reviews, 
 23, 529-549. doi: 10.1128/CMR.00082-09  
Gerding, D.N. (2010). Global epidemiology of Clostridium difficile infection in 2010. Infection 
Control and Hospital Epidemiology, 31F(S1), S32-S34. 
Khanna, S., Pardi, D.S., Aronson, S.L., Kammer, P.P., & Baddour, L.M. (2012). Outcomes in 
 community-acquired Clostridium difficile infection. Alimentary Pharmacology and 
 Therapeutics, 35, 613-618. doi: 10.1111/j.1365-2036.2011.04984.x 
Kuntz, J.L., Chrischilles, E.A., Pendergast, J.F., Herwaldt, L.A., & Polgreen, P.M. (2011). Incidence 
 of and risk factors for community-associated Clostridium difficile infection: A nested 
 case-control study. Biomed Central Infectious Diseases, 11, 194-100. 
Louie, T., Miller, M., Donskey, C., Mullane, K. & Goldstein E.J.C. (2009). Clinical outcomes, 
 safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium 
 difficile infection. Antimicrobial Agents and Chemotherapy, 53, 223-228. doi: 
 10.1128/AAC.01442-07 
Louie, T.J., Miller, M.A., Mullane, K.M., Weiss, K., Lentnek, A.,…Shue, Y.K. (2011). Fidaxomicin 
 versus Vancomycin for Clostridium difficile infection. New England Journal of Medicine, 
 364, 422-431. 
FIDAXOMICIN IS A SUPERIOR TREATMENT TO VANCOMYCIN FOR RECCURENT CLOSTRIDIUM 
DIFFICLE INFECTION   20 
LoVecchio, A. & Zacur, G.M. (2012). Clostridium difficile infection: an update on epidemiology, 
 risk factors, and therapeutic options. Current Opinion in Gastroenterology, 28, 1-9. doi: 
 10.1097/MOG.0b013e32834bc9a9 
Mayo Clinic. (2010). C. difficile: symptoms. Retrieved from  http://www.mayoclinic.com/ 
 health/c-difficile/DS00736/DSECTION=symptoms  
McFarland, L.V. (2008). Renewed interest in a difficult disease: Clostridium difficile infections – 
 epidemiology and current treatment strategies. Current Opinions in Gastroenterology, 
 25, 24-35. doi: 10.1097/MOG.0b013e32831da7c4 
Miller, M. (2010). Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. 
 Expert Opinion in Pharmacotherapy, 11, 1569-1578. 
Mullane, K.M., Miller, M.A., Weiss, K., Lentnek, A., Golan, Y., Sears, P.S.,…Gorbach, S.L. (2011). 
 Efficacy of Fidaxomicin versus Vancomycin as therapy for Clostridium difficile infection in 
 individuals taking concomitant antibiotics for other concurrent infections. Clinical 
 Infectious Diseases, 53, 440-447. doi: 10.1093/cid/cir404 
Noren, T. (2010). Clostridium difficile and the disease it causes. In Mullany, P. & Roberts, A.P. 
 (Eds.), Methods in Molecular Biology (pp. 9-35). Totawa, NJ: Humana Press. 
Peterson, H. (2011). Optimer wins FDA panel’s backing for antibiotic Fidaxomicin, Bloomberg. 
  Retrieved from http://www.bloomberg.com/news/2011-04-05/optimer-wins-fda-
 advisory-panel-s-backing-for-fidaxomicin-1-.html 
FIDAXOMICIN IS A SUPERIOR TREATMENT TO VANCOMYCIN FOR RECCURENT CLOSTRIDIUM 
DIFFICLE INFECTION   21 
Prabaker, K. & Weinstein, R.A. (2011). Trends in antimicrobial resistance in intensive care units 
 in the United States. Current Opinion in Critical Care, 17, 472-479. doi: 
 10.1097/MCC.0b013e32834a4b03 
Sullivan, K.M. & Spooner, L.M. (2010). Fidaxomicin: A macrocyclic antibiotic for the 
 management of Clostridium difficile infection. The Annals of Pharmacotherapy, 44, 352-
 359. 
Tannock, G.W., Munro, K., Taylor, C., Lawley, B., Young, W., Byrne, B.,… & Louie, T. (2010). A 
 new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel 
 microbiota of Clostridium difficile-infected patients than does Vancomycin. 
 Microbiology, 156, 3354-3359. doi: 10.1099/mic0.042010-0 
U.S. Food and Drug Administration. (2010). Fidaxomicin: Label and approval history. Retrieved 
 from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdf  
U.S. Food and Drug Administration. (2010). Flagyl: Label approval and history. Retrieved from 
 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.L
 abel_ApprovalHistory#apphist 
Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J.,…McDonald, L.C. (2005). 
 Toxin production by an emerging strain of Clostridium difficile associated with outbreaks 
 of severe disease in North America and Europe. Lancet, 366, 1079-1084. 
FIDAXOMICIN IS A SUPERIOR TREATMENT TO VANCOMYCIN FOR RECCURENT CLOSTRIDIUM 
DIFFICLE INFECTION   22 
Xu, J., Kochanek, K.D., Murphy, S.L. & Tejada-Vera, B. (2010). Deaths: Final data for 2007 
 (National Vital Statistics Report v.58, No. 19). Hyattsville, MD: National Center for Health 
 Statistics.  
 
 
